» Articles » PMID: 36033224

Quality of Life in Patients with Fabry's Disease: a Cross-sectional Study of 86 Adults

Abstract

Background: Fabry disease (FD) is a multi-organ disorder associated with severe physical and psychological impairments, particularly in adulthood. To date, comprehensive data on the psychological burden of FD are lacking. The present study assessed quality of life (QOL) in a representative cohort of adults with FD.

Methods: Patient-reported outcome measures were retrospectively analyzed in 86 adults with FD (49.6±16.6 years; 62.8% female) and compared to adults with congenital heart defects (ACHD) which is another lifelong disease and affliction. QOL was assessed using the European Quality of Life 5 Dimensions 5 Levels questionnaire (EQ-5D-5L).

Results: Subjects affected by FD reported an overall reduced QOL (EQ-VAS: 71.8±20.0). Most frequently reported complaints occurred within the dimensions pain/discomfort (69.7%), daily activities (48.9%) and anxiety/depression (45.4%). Compared to ACHD, individuals with FD scored significantly lower in the areas of pain/discomfort, usual activities and mobility (all P<0.05). Older age and female sex were particularly associated with diminished QOL (P=0.05).

Conclusions: Patients with FD are at high risk for impaired QOL. They require additional support to cope with disease-related challenges. Increased attention should be directed towards improving their subjective well-being to potentially increase their QOL and long-term health outcomes.

Citing Articles

Fatigue as hallmark of Fabry disease: role of bioenergetic alterations.

Gambardella J, Riccio E, Bianco A, Fiordelisi A, Cerasuolo F, Buonaiuto A Front Cardiovasc Med. 2024; 11:1341590.

PMID: 38327490 PMC: 10847249. DOI: 10.3389/fcvm.2024.1341590.

References
1.
Linhart A, Palecek T . Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations. Cardiovasc Diagn Ther. 2021; 11(2):650-660. PMC: 8102243. DOI: 10.21037/cdt-20-593. View

2.
Oder D, Muntze J, Nordbeck P . Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review. Cardiovasc Diagn Ther. 2021; 11(2):683-695. PMC: 8102271. DOI: 10.21037/cdt-20-743. View

3.
Polistena B, Rigante D, Sicignano L, Verrecchia E, Manna R, dAngela D . Survey about the Quality of Life of Italian Patients with Fabry Disease. Diseases. 2021; 9(4). PMC: 8544536. DOI: 10.3390/diseases9040072. View

4.
Ali N, Gillespie S, Laney D . Treatment of Depression in Adults with Fabry Disease. JIMD Rep. 2017; 38:13-21. PMC: 5874216. DOI: 10.1007/8904_2017_21. View

5.
Andonian C, Freilinger S, Achenbach S, Ewert P, Gundlach U, Hoerer J . 'Well-being paradox' revisited: a cross-sectional study of quality of life in over 4000 adults with congenital heart disease. BMJ Open. 2021; 11(6):e049531. PMC: 8220527. DOI: 10.1136/bmjopen-2021-049531. View